| Pharmaceutical Information |
| Drug Name |
Physostigmine |
| Drug ID |
BADD_D01768 |
| Description |
A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. |
| Indications and Usage |
For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity. |
| Marketing Status |
approved; investigational |
| ATC Code |
S01EB05; V03AB19 |
| DrugBank ID |
DB00981
|
| KEGG ID |
D00196
|
| MeSH ID |
D010830
|
| PubChem ID |
5983
|
| TTD Drug ID |
D09JVV
|
| NDC Product Code |
Not Available |
| UNII |
9U1VM840SP
|
| Synonyms |
Physostigmine | Eserine |
|
| Chemical Information |
| Molecular Formula |
C15H21N3O2 |
| CAS Registry Number |
57-47-6 |
| SMILES |
CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
